Have a feature idea you'd love to see implemented?
Let us know!
VCEL Vericel Corp
Price (delayed)
$59.11
Market cap
$2.92B
P/E Ratio
844.43
Dividend/share
N/A
EPS
$0.07
Enterprise value
$2.94B
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured
Highlights
The net income has soared by 135% YoY
The EPS has soared by 132% YoY
The debt rose by 15% YoY
The quick ratio has declined by 14% year-on-year
Key stats
What are the main financial stats of VCEL
Market
Valuations
Earnings
Shares outstanding
49.36M
Market cap
$2.92B
Enterprise value
$2.94B
Price to earnings (P/E)
844.43
Price to book (P/B)
11.26
Price to sales (P/S)
12.79
EV/EBIT
559.4
EV/EBITDA
169.64
EV/Sales
12.98
Revenue
$226.84M
EBIT
$5.26M
EBITDA
$17.36M
Free cash flow
-$12.02M
Per share
Balance sheet
Liquidity
EPS
$0.07
Free cash flow per share
-$0.24
Book value per share
$5.25
Revenue per share
$4.62
TBVPS
$7.82
Total assets
$390.41M
Total liabilities
$132.93M
Debt
$97.46M
Equity
$257.47M
Working capital
$149.17M
Debt to equity
0.38
Current ratio
4.61
Quick ratio
4.04
Net debt/EBITDA
1.56
Margins
Efficiency
Dividend
EBITDA margin
7.7%
Gross margin
71.5%
Net margin
1.6%
Operating margin
-0.5%
Return on assets
1%
Return on equity
1.5%
Return on invested capital
1.6%
Return on capital employed
1.5%
Return on sales
2.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCEL stock price
How has the Vericel stock price performed over time
Intraday
4.23%
1 week
12.63%
1 month
41.31%
1 year
66.55%
YTD
65.99%
QTD
39.91%
Financial performance
How have Vericel's revenue and profit performed over time
Revenue
$226.84M
Gross profit
$162.12M
Operating income
-$1.23M
Net income
$3.55M
Gross margin
71.5%
Net margin
1.6%
The net income has soared by 135% YoY
The net margin has soared by 129% YoY
Vericel's operating margin has soared by 93% YoY and by 72% from the previous quarter
Vericel's operating income has surged by 91% YoY and by 68% QoQ
Growth
What is Vericel's growth rate over time
Valuation
What is Vericel stock price valuation
P/E
844.43
P/B
11.26
P/S
12.79
EV/EBIT
559.4
EV/EBITDA
169.64
EV/Sales
12.98
The EPS has soared by 132% YoY
VCEL's price to book (P/B) is 27% higher than its last 4 quarters average of 8.9 and 22% higher than its 5-year quarterly average of 9.2
The equity rose by 26% year-on-year and by 6% since the previous quarter
VCEL's price to sales (P/S) is 31% higher than its 5-year quarterly average of 9.8 and 28% higher than its last 4 quarters average of 10.0
The revenue has grown by 22% YoY and by 6% from the previous quarter
Efficiency
How efficient is Vericel business performance
The ROS has soared by 146% YoY and by 130% from the previous quarter
The ROIC has soared by 143% year-on-year and by 129% since the previous quarter
VCEL's ROE has soared by 129% YoY
Vericel's return on assets has surged by 129% YoY
Dividends
What is VCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCEL.
Financial health
How did Vericel financials performed over time
The total assets is 194% higher than the total liabilities
The total assets has increased by 23% YoY and by 3.6% QoQ
Vericel's total liabilities has increased by 17% YoY
The debt is 62% lower than the equity
The equity rose by 26% year-on-year and by 6% since the previous quarter
The debt rose by 15% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.